Indoco Remedies gains on getting EU GMP certification for Baddi facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Indoco Remedies is currently trading at Rs. 330.00, up by 1.10 points or 0.33% from its previous closing of Rs. 328.90 on the BSE.
The scrip opened at Rs. 329.40 and has touched a high and low of Rs. 334.95 and Rs. 326.20 respectively. So far 4147 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 423.10 on 02-Jan-2023 and a 52 week low of Rs. 307.00 on 26-Apr-2023.
Last one week high and low of the scrip stood at Rs. 354.75 and Rs. 326.20 respectively. The current market cap of the company is Rs. 3055.71 crore.
The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 19.60% and 21.70% respectively.
Indoco Remedies has received EU GMP certification from the Competent Health Authority of Germany for its manufacturing site situated at HB 211 Village Katha, Baddi, Tehsil- Nalagarh, District - Solan. The Agency conducted an inspection at Indoco’s manufacturing facility for oral dosage form (Baddi -III), from May 22 - 25, 2023.
The EU GMP certification issued by the German Health Authority (Berlin) confirms that the site complies with the Good Manufacturing Practice requirements as referred in the EC Directive. The EU certification will support supplies of drug products registered in Europe, from this manufacturing site.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
